NewsRoom Articles - Page 144 of 223

FridayNov 05, 2021 9:30 am

Climate Change Takes Heavy Toll on Mental Health

As the 26th Climate Change Conference (CoP26) gets underway, a number of experts are calling attention to the detrimental effects that climate change has on mental health. These experts say this component isn’t being given as much attention as it deserves by policymakers. According to a recent report released by the World Health Organization, climate change is the most significant threat to health that humanity faces. Already, the world is witnessing loss of life due to extreme heat events, waterborne diseases, zoonotic diseases, and malnutrition among other such climate-related causes of mortality. While the climate change threats above aren’t receiving…

FridayNov 05, 2021 7:36 am

Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Validates its AI-Driven Drug Discovery Program with Successful Synthesis of Novel Tryptamine; Confirms Participation in the Wonderland: Miami Psychedelic Medicine Business Event

Mydecine just announced the successful synthesis of a novel psilocin analogue, a tryptamine The achievement adds to the company’s library of patent-pending tryptamines for medical use and therapy, and is seen as verifying the value of Mydecine’s AI-driven drug discovery program Mydecine has also confirmed its participation in the Wonderland: Miami psychedelic medicine event scheduled for November 8-9, 2021, where the company will share its recent research advancements and goals going forward Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) just announced the successful synthesis of a novel psilocin analogue, a tryptamine, that has proven to have improved pharmaceutical properties (https://ibn.fm/I2lX7).…

ThursdayNov 04, 2021 12:50 pm

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Marks Another Significant Milestone with IND Application for Fibromyalgia Phase 2a Clinical Trial

Tryp just filed an IND with the FDA for its TRP-8802 clinical candidate for its Phase 2a clinical trial The trial is set to commence in 2022, subject to a favorable review by the FDA The study will be conducted in collaboration with the University of Michigan and will aim at evaluating the safety and clinical utility of psilocybin for fibromyalgia Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced its submission of an Investigational New Drug (“IND”) application to the United States Food and Drug Administration (“FDA”) for its TRP-88802 clinical candidate. This application follows the commencement of Tryp’s Phase…

ThursdayNov 04, 2021 12:33 pm

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Growth Strategy Moves Forward with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) Partnership for Ketamine-Assisted Psychotherapy Distribution

The distribution component unlocks a new revenue source for the company, helping drive future growth MINDCURE’s platform was built as a digital tool and distribution platform, and has already been used for deployment and distribution of ketamine for depression and pain Digital therapeutics market is projected to reach USD $13.1 billion by 2026 from USD $3.4 billion in 2021 at a CAGR of 31.4 %, a substantial increase primarily driven by the COVID-19 pandemic and the stressors associated with it MINDCURE’s target areas and value proposition list numerous benefits for therapists, patients, payers, and drug and protocol developers, through the…

ThursdayNov 04, 2021 9:30 am

Patient Attitudes on Colorectal Cancer Screening Shifted During Pandemic

A recent survey has found that the rates of screening for colorectal cancer using colonoscopies dipped during the COVID-19 pandemic while there was an improvement in the number of people opting for at-home tests for this disease during that time. Previous studies have aptly documented how patients were reluctant to honor their doctor appointments for illnesses that were not related to the coronavirus. However, a team of researchers from Virginia Commonwealth University (“VCU”) wanted to obtain an accurate picture of the situation with respect to colorectal cancer screening. Not surprisingly, the team established that reluctance levels were high among patients…

WednesdayNov 03, 2021 9:30 am

How Medical Research Can Leverage AI Without Risking Personal Data

Artificial intelligence (“AI”) can be used to accelerate research and advance healthcare. It can also play a crucial role in conducting clinical trials and drug research. Using artificial intelligence to pool medical data helps save lives because AI surpasses humans in diagnosing conditions and choosing treatments. However, pooling medical data and centralizing it is unethical, given that it doesn’t align with patient privacy conditions. Centralizing data from millions of individuals also makes it vulnerable to misuse, breaches and hacks. So, how can we yield the same benefits as pooling data without sharing patient data? Sharing data is impossible, mainly because…

TuesdayNov 02, 2021 9:30 am

Research Finds That Brain Tumors Spread in a Calculated Manner

For the longest time, researchers thought that the process through which cancer spread to other parts of the body, in particular the brain, was random. However, a recent study conducted by researchers at the University of Southern California has found that cancer spread to other parts of the body in a somewhat organized manner. For their study, the researchers carried out an analysis of more than 3,100 brain tumors that originated from cancers in the colon, kidney, breast, lung or skin of more than 900 patients who received treatment at the Keck Medical Center; the patients were treated during 1994–2015.…

MondayNov 01, 2021 1:19 pm

Successful Ginkgo Bioworks SPAC IPO Highlights Available Industry Opportunities for InMed Pharmaceuticals Inc. (NASDAQ: INM) and Synthetic Cannabinoid Production

Special purpose acquisition company Soaring Eagle Acquisition Corp. combined with Ginkgo Bioworks to form publicly listed Ginkgo Bioworks Holdings Inc., in what is the largest-ever biotechnology go-public transaction Ginkgo Bioworks is known for its work in the commercial-scale production of a rare cannabinoid, CBG, for use in a multitude of industrial needs InMed uses multiple manufacturing approaches to synthetically produce rare cannabinoids, including CBC which is currently sold through its subsidiary BayMedica The success of the Ginkgo IPO suggests the marketplace value associated with the production of rare cannabinoids Special purpose acquisition company (“SPAC”) Soaring Eagle Acquisition Corp. (NASDAQ: SRNGU,…

MondayNov 01, 2021 11:06 am

Study Sheds Light on Genesis of Phantom Limb Pain

A recent study reported in “Scientific Reports” has discovered that after an individual’s limb is amputated, areas in the brain that are responsible for sensation and movement modify their functional communication. Functional communication refers to the communication of different areas of the brain. The study, which was conducted by researchers from the Federal University of Rio de Janeiro and the D’Or Institute for Research and Education, may assist physicians in better understanding why some amputees don’t report phantom sensations while others do. Their research also represents an advancement toward the complete understanding of the brain’s ability to alter itself in…

FridayOct 29, 2021 11:48 am

Obstructive Sleep Apnea May Be Affecting Productivity in Workplace

The National Institutes of Health estimates that about 25 million individuals in America suffer from obstructive sleep apnea. Obstructive sleep apnea is a common sleep disorder that causes an individual’s breathing to start and stop while they’re asleep. The disorder affects an individual’s sleep and increases their risk for accidents as well as other diseases. It has many symptoms, the most common one being loud snoring. Other symptoms include excessive irritability, sore throat, dry mouth and morning headaches. It should be noted that not every person who snores has obstructive sleep apnea. However, individuals who experience loud snoring and gasping…